Bing-Neel Syndrome: Managing Patients With Waldenström Macroglobulinemia Characterized by CNS Involvement
According to the authors, treatment of patients with Bing-Neel syndrome should involve the use of CNS-penetrating approaches.
Diagnosis & Disease Information
Subtype of CXCR4 Mutation Correlated With Inferior Response to Ibrutinib in Waldenström Macroglobulinemia
Nonsense mutations in CXCR4, but not frameshift mutations, were associated with poor response compared with no mutation in CXCR4.
Using a Risk-Based System to Predict Progression From Asymptomatic Waldenström Macroglobulinemia
The model stratified patients into 3 risk groups based on median time to disease progression.
Frontline Rituximab Plus Bendamustine in Waldenström Macroglobulinemia
Outcome data from 222 patients with active Waldenstrom macroglobulinemia who were treated at the Mayo Clinic over 18 years were retrospectively reviewed.
Measuring Patient-Reported Outcomes in Waldenström Macroglobulinemia Patients Receiving Rituximab vs Ibrutinib-Rituximab
Researchers sought to further evaluate data on patient-reported outcomes from the iNNOVATE study.
Ibrutinib Dose Reduction Did Not Affect PFS in Waldenström Macroglobulinemia
The need for dose reductions did not significantly affect progression-free survival in patients with WM treated with ibrutinib.
Pivotal Trial Underway for Zanubrutinib in Waldenström Macroglobulinemia
The safety and efficacy of investigational agent zanubrutinib is being evaluated in a head-to-head phase 3 trial in Waldenström macroglobulinemia.
Ibrutinib Plus Rituximab Granted FDA Approval for Waldenström Macroglobulinemia
Rituximab plus ibrutinib is the first nonchemotherapy combination regimen approved in Waldenström macroglobulinemia.
Imbruvica Plus Rituximab Approved for Waldenström’s Macroglobulinemia
This expanded approval was based on results from the iNNOVATE study, a double-blind, placebo-controlled trial evaluating Imbruvica in combination with rituximab vs placebo + rituximab in 150 patients with either relapsed/refractory disease or previously untreated Waldenström’s macroglobulinemia.
Soluble PD-1 Ligands May Contribute to the Pathogenesis of Waldenström Macroglobulinemia
New evidence appears to support the potential utility of checkpoint inhibitors in Waldenström macroglobulinemia.
- Loading...
Loading...
Next post in Lymphoma
Loading... 
Loading...